FDA Grants Priority Review to Merck ’s Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) for Treatment of Recurrent or Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Dateline City:
KENILWORTH, N.J. Data Supporting Application to Be Presented at 2017 ASCO Annual MeetingKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today that the U.S. Food and Drug Administration (FDA) has
accepted for review a supplemental Biologics License Application (sBLA)
for KEYTRUDA® (pembrolizumab), the company ’s anti-PD-1
therapy, seeking approval for treatment of patients with recurrent or
advanced gastric or gastroesophageal junction adenocarcinoma who have
already received two or more lines of chemo...
Source: Merck.com - Product News - May 23, 2017 Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK cancer Keytruda MSD NYSE:MRK Source Type: news
Merck Receives CHMP Positive Opinion Recommending Approval of ISENTRESS ® (raltegravir) 600 mg in the European Union
Dateline City:
KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the Committee for Medicinal Products for Human
Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive
opinion recommending approval of ISENTRESS® (raltegravir) 600
mg film-coated tablets, in combination with other anti-retroviral
medicinal products, for the treatment of HIV-1 infection in adults and
pediatric patients weighing at least 40 kg.Language:
EnglishContact: MerckMedia:Pam Eisele, 267-30...
Source: Merck.com - Product News - May 19, 2017 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news
FDA Approves Merck ’s KEYTRUDA® (pembrolizumab) for Certain Patients with Locally Advanced or Metastatic Urothelial Carcinoma, a Type of Bladder Cancer
Dateline City:
KENILWORTH, N.J. Now Approved for First-Line Treatment in Patients Ineligible for Cisplatin-Containing Chemotherapy and Second-Line Treatment in Patients Who Have Disease Progression During or Following Platinum-Containing Chemotherapy or Within 12 Months of Neoadjuvant or Adjuvant Treatment with Platinum-Containing Chemotherapy KEYTRUDA is the Only Anti-PD-1 Therapy to Demonstrate Superior Overall Survival Versus Chemotherapy in Patients With Advanced Urothelial Carcinoma Post-Platinum FailureKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the Unit...
Source: Merck.com - Product News - May 18, 2017 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK NYSE:MRK Source Type: news
Merck to Present New Phase 3 Data on Investigational Ertugliflozin, Additional Analyses of Studies of JANUVIA ® (sitagliptin), and Real-World Evidence Research at the 77th Scientific Sessions of the American Diabetes Association
Dateline City:
KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that 19 scientific presentations from Merck ’s diabetes
pipeline and portfolio – including Phase 3 data for investigational
ertugliflozin, additional analyses of JANUVIA® (sitagliptin),
and real-world research – will be presented at the 77th
Scientific Sessions of the American Diabetes Association (ADA) in San
Diego, June 9-13, 2017.Language:
EnglishContact: MerckMedia:Doris Li, 908-246-5701Kristen Drake, 908-740-6179o...
Source: Merck.com - Product News - May 16, 2017 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news
FDA Approves Merck ’s KEYTRUDA® (pembrolizumab) as First-Line Combination Therapy with Pemetrexed and Carboplatin for Patients with Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC), Irrespective of PD-L1 Expression
Dateline City:
KENILWORTH, N.J. First Approval for an Anti-PD-1 Therapy as a Combination in Metastatic Nonsquamous NSCLCKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced that the U.S. Food and Drug Administration (FDA) has
approved KEYTRUDA® (pembrolizumab), the company ’s anti-PD-1
therapy, in combination with pemetrexed (brand name Alimta®)
and carboplatin (pem/carbo), a commonly used chemotherapy regimen, for
the first-line treatment of metastatic nonsquamous NSCLC, irrespective
of PD-L1 expression.Language...
Source: Merck.com - Product News - May 10, 2017 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK cancer Keytruda MSD NYSE:MRK Source Type: news
European Commission Approves KEYTRUDA ® (pembrolizumab) for Patients with Relapsed or Refractory Classical Hodgkin Lymphoma Who Failed Autologous Stem Cell Transplant and Brentuximab Vedotin (BV), or Who are Transplant-Ineligible and Have Failed BV
Dateline City:
KENILWORTH, N.J. First Approval for KEYTRUDA in a Hematologic Malignancy in the EUKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the European Commission has approved KEYTRUDA®
(pembrolizumab), the company ’s anti-PD-1 therapy, for the treatment of
adult patients with relapsed or refractory classical Hodgkin lymphoma
(cHL)who have failed autologous stem cell transplant (ASCT) and
brentuximab vedotin (BV), or who are transplant-ineligible and have
failed BV.Language:
EnglishContact: ...
Source: Merck.com - Product News - May 5, 2017 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK Classical Hodgkin Lymphoma Keytruda MSD NYSE:MRK Source Type: news
Real-World Observational Study in the U.S. Veterans Affairs System Evaluating Use of Merck ’s ZEPATIER® (Elbasvir and Grazoprevir) Shows High Sustained Virologic Response Rates in Patients with Chronic Hepatitis C
Dateline City:
KENILWORTH, N.J. Study Evaluated VA Population with High Incidence of Co-MorbiditiesKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada,
today announced the presentation of findings from a retrospective
database analysis of patients with chronic hepatitis C virus (HCV)
infection who were administered ZEPATIER®in the U.S.
Department of Veterans Affairs (VA) healthcare system.Language:
EnglishContact: Merck& Co., Inc.Media:Doris Li, 908-740-1903orMichael Close, 267-305-1211orInvestors:Teri Loxam, 908-740-1986or...
Source: Merck.com - Product News - April 21, 2017 Category: Drugs & Pharmacology Tags: Hepatitis C Newsroom Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK MSD NYSE:MRK ZEPATIER Source Type: news
Merck to Present New Data on ZEPATIER ® (elbasvir and grazoprevir) and Investigational Combination Therapy MK-3682B for the Treatment of Chronic Hepatitis C Infection at The International Liver Congress™ 2017
Dateline City:
KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada,
today announced that new data from the company ’s chronic hepatitis C
virus (HCV) clinical development programs as well as real-world studies
on ZEPATIER® (elbasvir and grazoprevir) 50mg/100mg tablets
will be presented at the upcomingInternational
Liver Congress ™ 2017. Seventeen scientific abstracts will be
presented, including oral sessions featuring real-world data on chronic
HCV-infected patients treated with ZEPATIER from the U.S.Language:
...
Source: Merck.com - Product News - April 5, 2017 Category: Drugs & Pharmacology Tags: Hepatitis C Newsroom Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK International Liver Congress MSD NYSE:MRK ZEPATIER Source Type: news
European Medicines Agency ’s CHMP Recommends Approval of Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma
Dateline City:
KENILWORTH, N.J. Recommendation Is for Adult Patients Who Have Failed Autologous Stem Cell Transplant and Brentuximab Vedotin (BV), or Who Are Transplant-Ineligible and Have Failed BVKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today that the Committee for Medicinal Products for Human Use
(CHMP) of the European Medicines Agency (EMA) has adopted a positive
opinion recommending approval of KEYTRUDA® (pembrolizumab),
the company ’s anti-PD-1 therapy, for the treatment of adult patients
with relapsed o...
Source: Merck.com - Product News - March 24, 2017 Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK Keytruda MSD NYSE:MRK Source Type: news
Merck Receives FDA Acceptance of Supplemental Biologics License Application for KEYTRUDA ® (pembrolizumab) in Combination with Chemotherapy for First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer
Dateline City:
KENILWORTH, N.J. Submission Based on Data from KEYNOTE-021 Trial, Cohort G, Which Enrolled Patients Regardless of PD-L1 ExpressionKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced that the U.S.Language:
EnglishContact: MerckMedia:Pamela Eisele, 267-305-3558orCourtney Ronaldo, 908-236-1108orInvestor:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898Ticker Slug:Ticker:MRKExchange:NYSE
@Merckread more (Source: Merck.com - Product News)
Source: Merck.com - Product News - January 10, 2017 Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK Keytruda Lung Cancer MSD NYSE:MRK Source Type: news
Incyte and Merck to Advance Clinical Development Program Investigating the Combination of Epacadostat with KEYTRUDA ® (pembrolizumab)
Dateline City:
WILMINGTON, D.E.& KENILWORTH, N.J.Additional pivotal studies evaluating Incyte ’s IDO1 inhibitor in combination with Merck’s anti-PD-1 therapy in patients with non-small cell lung, renal, bladder and head and neck cancers expected to start in 2017WILMINGTON, D.E.& KENILWORTH, N.J.–Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the decision to advance the clinical development program investigating the combination of epacadostat, Incyte ’s investigational oral selective IDO1 inhibitor, with KEYTRUDA® (pembrolizumab), ...
Source: Merck.com - Product News - January 9, 2017 Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News Source Type: news
KEYTRUDA ® (pembrolizumab) Approved as First Anti-PD-1 Therapy in Japan for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express High Levels of PD-L1
Dateline City:
KENILWORTH, N.J. KEYTRUDA Also Approved for Second-Line Treatment of Patients with Advanced NSCLC Whose Tumors Express PD-L1KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that KEYTRUDA® (pembrolizumab), the company ’s
anti-PD-1 therapy, has been approved in Japan for the treatment of
certain patients with PD-L1-positive unresectable advanced/recurrent
non-small cell lung cancer (NSCLC) in the first- and second-line
treatment settings at a fixed dose of 200 mg every three weeks. MS D will
manufa...
Source: Merck.com - Product News - December 19, 2016 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK Keytruda MSD NYSE:MRK Source Type: news
KEYTRUDA ® (pembrolizumab) Demonstrated Improved Health-Related Quality of Life Compared to Chemotherapy in First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC)
Dateline City:
KENILWORTH, N.J. First Presentation of Patient-Reported Outcomes from KEYNOTE-024 Study of Patients with Metastatic NSCLC Whose Tumors Have High PD-L1 Expression (Tumor Proportion Score [TPS] of 50 Percent or More) Findings Presented in Plenary Session at 17 th World Conference on Lung CancerKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced positive health-related quality of life (HRQoL) findings
from an exploratory analysis from the phase 3 KEYNOTE-024 study
investigating the use of KEYTRUDA® (pembro...
Source: Merck.com - Product News - December 7, 2016 Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK KETYRUDA MSD NSCLC NYSE:MRK Source Type: news
Updated KEYTRUDA ® (pembrolizumab) Data in Small Cell Lung Cancer and Mesothelioma Presented at 17th World Conference on Lung Cancer
Dateline City:
KENILWORTH, N.J. Findings in Small Cell Lung Cancer and Malignant Pleural Mesothelioma Show Overall Response Rates of 33.3 Percent and 20.0 Percent, Respectively, in KEYNOTE-028 Long-Term Data Demonstrate Durable Responses in Difficult-to-Treat CancersKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that updated findings from the phase 1b KEYNOTE-028
study investigating the use of KEYTRUDA® (pembrolizumab), the
company ’s anti-PD-1 therapy, in previously treated patients with
advanced small cell...
Source: Merck.com - Product News - December 6, 2016 Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK Keytruda Lung Cancer MSD NYSE:MRK Source Type: news
KEYTRUDA ® (pembrolizumab) Treatment Results in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) Presented at 58th Annual Meeting of the American Society of Hematology
Dateline City:
KENILWORTH, N.J. Data from Pivotal KEYNOTE-087 Trial Show Overall Response Rate (ORR) of 69.0 Percent and Complete Remission Rate (CRR) of 22.4 Percent With More than Two Years of Follow-up, Findings from KEYNOTE-013 Show ORR of 58 Percent and CRR of 19 Percent with Responses of 12 Months or Greater in 70 Percent of Responding PatientsKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today updated findings evaluating KEYTRUDA®
(pembrolizumab), the company ’s anti-PD-1 therapy, in two trials of
patients wit...
Source: Merck.com - Product News - December 6, 2016 Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK ASH Keytruda MSD NYSE:MRK Source Type: news
